Linked e-resources
Details
Table of Contents
Preface; Contents; 1 Introduction; Abstract ; 1.1 The Rationale of Introducing Colloidal Carriers; 1.2 Introduction to Colloidal Drug Carriers; 1.3 Lipid Nanoparticles: History and Scope; 1.4 Lipid Nanoparticles: Types; 1.4.1 Solid Lipid Nanoparticle (SLN); 1.4.2 Nanostructured Lipid Carrier (NLC); 1.4.3 Lipid Drug Conjugate (LDC); 1.4.4 Polymer-Lipid Hybrid Nanoparticle (PLN); References; 2 Composition and Structure; Abstract ; 2.1 Composition of Lipid Nanoparticles; 2.1.1 Lipids; 2.1.2 Surfactants; 2.1.3 Other Agents; 2.2 Structure of Solid Lipid Nanoparticles.
2.2.1 Drug-Enriched Shell Model2.2.2 Drug-Enriched Core Model; 2.2.3 Solid Solution Model; 2.3 Structure of Nanostructured Lipid Carriers; 2.3.1 NLC Type I or "Imperfect Crystal" Type; 2.3.2 NLC Type II or "Multiple" Type; 2.3.3 NLC Type III or "Amorphous" Type; 2.4 Conclusions; References; 3 Production Techniques; Abstract ; 3.1 General Considerations; 3.2 Production of Lipid Nanoparticles; 3.2.1 High Pressure Homogenization; 3.2.1.1 Hot Homogenization; 3.2.1.2 Cold Homogenization; 3.2.2 Microemulsion Technique; 3.2.3 Microwave-Assisted Microemulsion Technique; 3.2.4 Solvent Evaporation.
3.2.5 Double Emulsion3.2.6 Solvent Diffusion; 3.2.7 Solvent Injection (or Displacement); 3.2.8 High Shear Homogenization andor Ultrasound; 3.2.9 Membrane Contactor Method; 3.2.10 Supercritical Fluid Extraction of Emulsions; 3.2.11 Coacervation Technique; 3.2.12 Phase Inversion Temperature Technique; 3.3 Conclusions; References; 4 Characterization; Abstract ; 4.1 Particle Size; 4.1.1 Photon Correlation Spectroscopy; 4.1.2 Laser Diffraction; 4.1.3 Field-Flow Fractionation; 4.1.4 Other Techniques; 4.2 Particle Morphology and Ultrastructure; 4.2.1 Transmission Electron Microscopy.
4.2.2 Scanning Electron Microscopy4.2.3 Atomic Force Microscopy; 4.3 Surface Charge; 4.4 Crystallinity and Polymorphism; 4.4.1 Differential Scanning Calorimetry; 4.4.2 X-ray Diffraction; 4.4.3 Small Angle X-ray Scattering; 4.5 Co-existence of Addition Colloidal Structures and Interaction with Incorporated Drugs; 4.5.1 Nuclear Magnetic Resonance; 4.5.2 Electron Spin Resonance; 4.6 Conclusions; References; 5 Physicochemical Stability; Abstract ; 5.1 General Considerations; 5.2 Stabilization Mechanisms; 5.2.1 Electrostatic Stabilization; 5.2.2 Steric Stabilization; 5.3 Destabilization Mechanisms.
5.3.1 Physical Stability5.3.1.1 Dispersion Modifications; 5.3.1.2 Lipid Modifications; 5.3.2 Chemical Stability; 5.3.2.1 Drug Stability; 5.3.2.2 Phospholipid Stability; 5.3.2.3 Lipid Stability; 5.4 Stability Measurements; 5.4.1 Physical Stability; 5.4.1.1 Modification of Size; 5.4.1.2 Modification of Zeta Potential; 5.4.1.3 Modification of Crystallinity and Polymorphism; 5.4.1.4 Optical Analysis by Turbiscan® Lab; 5.4.2 Chemical Stability; 5.5 Optimization of Stability; 5.5.1 Physical Stability; 5.5.1.1 Steric Stabilization; 5.5.1.2 Electrostatic Stabilization.
2.2.1 Drug-Enriched Shell Model2.2.2 Drug-Enriched Core Model; 2.2.3 Solid Solution Model; 2.3 Structure of Nanostructured Lipid Carriers; 2.3.1 NLC Type I or "Imperfect Crystal" Type; 2.3.2 NLC Type II or "Multiple" Type; 2.3.3 NLC Type III or "Amorphous" Type; 2.4 Conclusions; References; 3 Production Techniques; Abstract ; 3.1 General Considerations; 3.2 Production of Lipid Nanoparticles; 3.2.1 High Pressure Homogenization; 3.2.1.1 Hot Homogenization; 3.2.1.2 Cold Homogenization; 3.2.2 Microemulsion Technique; 3.2.3 Microwave-Assisted Microemulsion Technique; 3.2.4 Solvent Evaporation.
3.2.5 Double Emulsion3.2.6 Solvent Diffusion; 3.2.7 Solvent Injection (or Displacement); 3.2.8 High Shear Homogenization andor Ultrasound; 3.2.9 Membrane Contactor Method; 3.2.10 Supercritical Fluid Extraction of Emulsions; 3.2.11 Coacervation Technique; 3.2.12 Phase Inversion Temperature Technique; 3.3 Conclusions; References; 4 Characterization; Abstract ; 4.1 Particle Size; 4.1.1 Photon Correlation Spectroscopy; 4.1.2 Laser Diffraction; 4.1.3 Field-Flow Fractionation; 4.1.4 Other Techniques; 4.2 Particle Morphology and Ultrastructure; 4.2.1 Transmission Electron Microscopy.
4.2.2 Scanning Electron Microscopy4.2.3 Atomic Force Microscopy; 4.3 Surface Charge; 4.4 Crystallinity and Polymorphism; 4.4.1 Differential Scanning Calorimetry; 4.4.2 X-ray Diffraction; 4.4.3 Small Angle X-ray Scattering; 4.5 Co-existence of Addition Colloidal Structures and Interaction with Incorporated Drugs; 4.5.1 Nuclear Magnetic Resonance; 4.5.2 Electron Spin Resonance; 4.6 Conclusions; References; 5 Physicochemical Stability; Abstract ; 5.1 General Considerations; 5.2 Stabilization Mechanisms; 5.2.1 Electrostatic Stabilization; 5.2.2 Steric Stabilization; 5.3 Destabilization Mechanisms.
5.3.1 Physical Stability5.3.1.1 Dispersion Modifications; 5.3.1.2 Lipid Modifications; 5.3.2 Chemical Stability; 5.3.2.1 Drug Stability; 5.3.2.2 Phospholipid Stability; 5.3.2.3 Lipid Stability; 5.4 Stability Measurements; 5.4.1 Physical Stability; 5.4.1.1 Modification of Size; 5.4.1.2 Modification of Zeta Potential; 5.4.1.3 Modification of Crystallinity and Polymorphism; 5.4.1.4 Optical Analysis by Turbiscan® Lab; 5.4.2 Chemical Stability; 5.5 Optimization of Stability; 5.5.1 Physical Stability; 5.5.1.1 Steric Stabilization; 5.5.1.2 Electrostatic Stabilization.